FierceBiotech

Sangamo slashes time to market for Fabry gene therapy as FDA agrees to accelerated approval package

Sangamo Therapeutics has identified a shortcut to market for its Fabry disease candidate, aligning with the FDA on a pathway that could slash three years from the time to market and free it from the ...
TipRanks on MSN

Sangamo receives U.S. FDA Fast Track Designation to ST-503

Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation to ST-503, an ...

With cash running low, East Bay biotech Sangamo bets on FDA submission strategy

This East Bay company's FDA submission could lead to its first regulatory approval in three decades of operation.
Morningstar

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

RICHMOND, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced detailed data from the registrational Phase 1/2 STAAR study ...
Business Wire

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene ...